By Richard Saltus Though quite curable when diagnosed early, kidney cancer in advanced stages can become a stubborn disease. However, the outlook for patients with metastatic kidney cancer has brightened in the past several years. Oncologists have added to their arsenal a number of designer drugs that attack molecular targets – genetic abnormalities that drive tumors – with high specificity.
For about 70 years, the standard treatment for patients with advanced prostate cancer was drugs that blocked male hormones feeding the tumor. If that stopped working and the disease progressed, oncologists turned to chemotherapy to kill the cancer cells. This timetable is about to change. Results of a clinical trial led by a Dana-Farber researcher revealed that such patients lived longer if started on both a hormone blocker and a chemotherapy drug at the same time. The government-sponsored trial found that 69 percent of men receiving both treatments were alive at three years, compared with 52.5 percent of men who …
Dana-Farber Cancer Institute’s Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH recently partnered with CancerConnect to answer questions about breast cancer therapies. Burstein and Mayer are breast oncologists in the Center for Breast Oncology at Dana-Farber’s Susan F. Smith Center for Women’s Cancers. Q: What medications are helpful for depression after breast cancer treatment and while taking tamoxifen?
Ann LaCasce, MD, a medical oncologist in the Dana-Farber/Brigham and Women’s Cancer Center Adult Lymphoma Program, answered a variety of questions about Hodgkin and non-Hodgkin lymphoma during a live web chat hosted by Dana-Farber last month.
Experts with the U.S. Preventive Services Task Force (USPSTF) have recommended that current smokers and former-smokers who recently quit should undergo an annual low-dose CT scan to screen for lung cancer.
As 2013 comes to a close, we’re looking back at some of our favorite Insight posts from the last year. From inspiring patient stories to important research, here is our top 10 list:
An analysis of data from the decades-long Nurses’ Health Study revealed that women who ate a one-ounce serving of nuts – any kind of nuts – two or more times a week had a 35 percent lower risk of pancreatic cancer than women who abstained from them. That’s a significant and encouraging piece of news for a field that has had far too little.
The 36th annual San Antonio Breast Cancer Symposium, which ran from Dec. 10-14, brought news of significant advances against a disease that strikes more than 230,000 women and 2,000 men in the United States each year. The more than 1,000 research papers presented by thousands of scientists and physicians ranged from laboratory explorations of the basic biology of the disease to studies that may change the treatment for patients with a variety of breast cancer subtypes. Here are summaries of the findings of several high-profile studies:
While some people claim dairy products can prevent cancer, others argue that dairy could actually increase the cancer risk. There are also concerns that dairy can potentially spur growth in hormone-sensitive cancers, including some forms of ovarian and breast cancer. Is there a relationship between dairy and cancer? We consulted with the Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) Nutrition Department to find out.